Who owns Krystal Biotech, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KRYS from SEC Form 13F filings across 443 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 443 institutions disclosed 29.0M shares of Krystal Biotech, Inc. worth $9.64B — about 98% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
443
13F holders
$9.64B
value, 2026 filers
98%
of shares outstanding (29.0M sh)
80
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of KRYS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 4.4M | $1.48B | 0.1% | 15% | +0.5% |
| 2 | BlackRock, Inc. | 3.6M | $1.19B | 0.0% | 12.1% | -14.1% |
| 3 | Avoro Capital Advisors LLC | 2.9M | $960.7M | 9.9% | 9.8% | 0.0% |
| 4 | STATE STREET CORP | 1.4M | $472.3M | 0.0% | 4.8% | +5.1% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3M | $428.0M | 0.0% | 4.3% | -18.3% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $398.0M | 0.0% | 4% | -3.5% |
| 7 | Soleus Capital Management, L.P. | 1.1M | $379.0M | 13.5% | 3.8% | +21.3% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 811,735 | $270.0M | 0.0% | 2.7% | +16.1% |
| 9 | Capital World Investors | 779,264 | $259.2M | 0.0% | 2.6% | +0.2% |
| 10 | Hood River Capital Management LLC | 671,985 | $223.5M | 1.9% | 2.3% | +1.3% |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 586,437 | $195.0M | 0.0% | 2% | -14.7% |
| 12 | Redmile Group, LLC | 527,684 | $175.5M | 12.8% | 1.8% | -16.5% |
| 13 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 520,925 | $173.2M | 0.6% | 1.8% | -8.6% |
| 14 | DIMENSIONAL FUND ADVISORS LP | 470,028 | $156.3M | 0.0% | 1.6% | -1.3% |
| 15 | GOLDMAN SACHS GROUP INC | 429,739 | $142.9M | 0.0% | 1.5% | +43.8% |
| 16 | Frazier Life Sciences Management, L.P. | 391,319 | $130.1M | 3.2% | 1.3% | -18.7% |
| 17 | FRANKLIN TEMPLETON INC | 370,951 | $115.3M | 0.0% | 1.3% | +41.6% |
| 18 | Invesco Ltd. | 356,320 | $118.5M | 0.0% | 1.2% | +9.7% |
| 19 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 339,245 | $112.8M | 0.0% | 1.1% | +33.1% |
| 20 | NORTHERN TRUST CORP | 324,137 | $107.8M | 0.0% | 1.1% | +14.2% |
| 21 | BANK OF AMERICA CORP /DE/ | 269,550 | $89.6M | 0.0% | 0.9% | +5.1% |
| 22 | Janus Henderson Group Ltd.NEW | 247,484 | $82.3M | 0.0% | 0.8% | new |
| 23 | VANGUARD FIDUCIARY TRUST CO | 189,854 | $63.1M | 0.0% | 0.6% | +0.2% |
| 24 | WESTFIELD CAPITAL MANAGEMENT CO LP | 171,170 | $56.9M | 0.2% | 0.6% | +73.4% |
| 25 | JPMORGAN CHASE & CO | 167,450 | $56.6M | 0.0% | 0.6% | +91.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.